Figure 2.

Genome wide CRISPR to reveals genes controlling response to Temozolomide (TMZ)

(A) Temozolomide dose response curves of seven human glioma cell lines treated with Temozolomide (50–400 µM) and DMSO for 72 h. (b) Bar chart shows the most enriched guides for NSUN6 (blue, orange compared in TMZ, Puromycin days 0, 14 and DMSO day 14 (control)(Rep#1,2). (c&d) Western blots show edited NSUN6 in U251 and MES83 compared to non-targeting controls & wild type. (E, F relates to U251, G & H relates to MES83). Bar chart shows viability for SgNSUN6 edited cells and non-edited treated with TMZ (50 µM, 100 µM) for 72 h.